Posted by Michael Wonder on 29 Sep 2024
FDA approves selpercatinib for RET fusion-positive medullary thyroid cancer
27 September 2024 - Today, the FDA granted traditional approval to selpercatinib (Retevmo, Eli Lilly) for adult and paediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer with a RET mutation, as detected by an FDA approved test, who require systemic therapy.
Efficacy was evaluated in LIBRETTO-53, a randomised, multi-centre, open-label study in adults and adolescents with advanced or metastatic RET mutant medullary thyroid cancer.
